Published in Gene Therapy Weekly, July 21st, 2005
Inspire has completed more than 50% of target enrollment in its ongoing phase 2 safety study, which is a double-blind, randomized comparison of 2 doses of denufosol tetrasodium (INS37217 Respiratory) to placebo in 72 patients with CF at 18 clinical centers across the United States.
This second phase 2 trial is being conducted in order to gain a greater understanding of safety and tolerability of denufosol in a broader population of CF patients, including patients with lower lung function and patients using antibiotics and other therapeutics,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly